Whole Body Health Sale

Life Extension Magazine

LE Magazine March 2004
The DHEA Debate
A critical review of clinical and experimental data
References

1. Welle S, Jozefowicz R, Statt M. Failure of dehydroepiandrosterone to influence energy and protein metabolism in humans. J Clin Endocrinol Metab. 1990 Nov;71(5):1259-64.

2. Villareal DT, Holloszy JO, Kohrt WM. Effects of DHEA replacement on bone mineral density and body composition in elderly women and men. Clin Endocrinol. (Oxf) 2000 Nov;53(5):561-8.

3. Kawano H, Yasue H, Kitagawa A, et al. Dehydroepiandrosterone supplementation improves endothelial function and insulin sensitivity in men. J Clin Endocrinol Metab. 2003 Jul;88(7):3190-5.

4. Diamond P, Cusan L, Gomez JL, Belanger A, Labrie F. Metabolic effects of 12 month percutaneous dehydroepiandrosterone replacement therapy in postmenopausal women. J Endocrinol. 1996; 150:S43-S50.

5. Casson PR, Faquin LC, Stentz FB, et al. Replacement of dehydroepiandrosterone enhances T-lymphocyte insulin binding in postmenopausal women. Fertil Steril. 1995 May;63(5):1027-31.

6. Al-Harithy RN. Dehydroepiandrosterone sulfate levels in women; relationship with body mass index, insulin and glucose levels. Saudi Med J. 2003; 24(8):837-41.

7. Chiu KM, Schmidt MJ, Havighurst TC, et al. Correlation of serum L-carnitine and dehydro-epiandrosterone sulphate levels with age and sex in healthy adults. Age Ageing. 1999 Mar;28(2):211-6.

8. De Pergola G. The adipose tissue metabolism: role of testosterone and DHEA. Int J Obesity. 2000;24: Suppl 2. S59-S63.

9. Valtysdottir ST, Wide L, Hallgren R. Mental well-being and quality of sexual life in women with primary Sjogren’s syndrome are related to circulating dehydroepiandrosterone sulphate. Ann Rheum Dis. 2003 Sep;62(9):875-9.

10. Jozuka H, Jozuka E, Takeuchi S, Nishikaze O. Comparison of immunological and endocrinological markers associated with major depression. J Int Med Res. 2003 Jan-Feb;31(1):36-41.

11. Schmidt PJ, Murphy JH, Haq N, Danaceau MA, St Clair L. Basal plasma hormone levels in depressed perimenopausal women. Psychoneuroendocrinology. 2002 Nov;27(8):907-20.

12. Wolf OT, Neumann O, Hellhammer DH, et al. Effects of a two-week physiological dehydroepiandrosterone substitution on cognitive performance and well-being in healthy elderly women and men. J Clin Endocrinol Metab. 1997;82:2363-7.

13. Kudielka BM, Hellhammer J, Hellhammer DH, et al. Sex differences in endocrine and psychological responses to psychosocial stress in healthy elderly subjects and the impact of a two-week dehydroepiandrosterone treatment. J Clin Endocrinol Metab. 1998 May;83(5):1756- 61.

14. Morales AJ, Nolan JJ, Nelson JC, Yen SS. Effects of a replacement dose of dehy- droepiandrosterone in men and women of advancing age. J Endocrinol Metab. 1994 Jun; 78(6):1360-7.

15. Yen SS, Morales AJ, Khorram O. Replacement of DHEA in aging men and women. Ann NY Acad Sci. 1995 Dec 29; 774:128-42.

16. Baulieu EE. Dehydroepiandrosterone (DHEA): a fountain of youth? J Clin Endocrinol Metab. 1996 Sep;81(9):3147- 51.

17. van Broekhoven F, Verkes RJ. Neurosteroids in depression: a review. Psychopharmacology. (Berl). 2003 Jan;165(2):97-110. Epub 2002 Nov 06.

18. Nadjafi-Triebsch C, Huell M, Burki D, Rohr UD. Progesterone increase under DHEA-substitution in males. Maturitas. 2003 Jul 25;45(3):231-5.

19. Arlt W, Callies F, Allolio B. DHEA replacement in women with adrenal insufficiency—pharmacokinetics, bioconversion and clinical effects on well-being, sexuality and cognition. Endocr Res. 2000 Nov;26(4):505-11.

20. Wolkowitz OM, Reus VI, Roberts E, et al. Antidepressant and cognition-enhancing effects of DHEA in major depression. Ann NY Acad Sci. 1995 Dec 29;774:337-9.

21. Bloch M, Schmidt PJ, Danaceau MA, Adams LF, Rubinow DR. Dehydroepiandrosterone treatment of midlife dysthymia. Biological Psychiatry. 1999 Jun 15;45(12):1533-41.

22. Jesse RL, Loesser K, Eich DM, Qian YZ, Hess ML, Nestler JE. Dehydroepiandrosterone inhibits human platelet aggregation in vitro and in vivo. Ann NY Acad Sci. 1995 Dec 29;774:281- 90.

23. Barret-Connor E, Knaw KT, Yen SSC. A prospective study of dehydroepiandrosterone sulfate, mortality and cardiovascular disease. N Engl J Med. 1986 Dec 11; 315:1519-24.

24. Shono N, Kumagai S, Higaki Y, Nishizumi M, Sasaki H. The relationships of testosterone, estradiol, dehydroepiandrosterone-sulfate and sex hormone-binding globulin to lipid and glucose metabolism in healthy men. J Atherosclerosis and Thrombosis. 1996;3(1):45-51.

25. Okamoto K. Relationship between dehydroepiandrosterone sulfate and serum lipid levels in Japanese men. J Epidemiol. 1996 Jun;6(2):63-7.

26. Tagawa N, Tamanaka J, Fujinami A, et al. Serum dehydroepiandrosterone, dehy- droepiandosterone sulfate, and pregnenolone sulfate concentrations in patients with hyperthyroidism and hypothyroidism. Clin Chem. 2000 Apr; 46(4):523-528.

27. Inaudi P, Massafra C, Bernabei A, Antoni G, D’Antona N. Gonadotropin, prolactin and thyrotropin pituitary secretion after exogenous dehydroepiandrosterone sulfate administration in normal women. Horm Red. 1991;35(1):35-40.

28. Tagawa N, Tokano T, Fukata S, et al. Serum concentrations of androstenediol and androstenediol sulfate in patients with hyperthyroidism and hypothyroidism. Endocr J. 2001;48:345-54.

29. Vranckx R, Mechighel P, Savu L. Effect of dehydroepiandrosterone on rat thyroxine binding globulin, a protein upregulated during aging. Ann NY Acad Sci. 1995 Dec 29; 774:335-6.

30. Bickova M, Tallova J, Hill M, Vanuga A, Putz Z, Tomandl J. Effect of treatment of hypothyroidism on the plasma concentra- tions of neuroactive steroids and homocysteine. Clin Chem Lab Med. 2001; 39:753-7.

31. de Bruin VM, Vieira MC, Rocha MN, Viana GS. Cortisol and dehydroepiandosterone sulfate plasma levels and their relationship to aging, cognitive function, and dementia. Brain Cogn. 2002 Nov;50(2):316-23.

32. Ferrari E, Casarotti D, Muzzoni B, et al. Age-related changes of the adrenal secretory pattern: possible role in pathological brain aging. Brain Res Brain Res Rev. 2001 Nov;37(1-3):294-300.

33. Wisniewski TL, Hilton CW, Morse EV, Svec F. The relationship of serum DHEAS and cortisol levels to measures of immune function in Human Immunodeficiency Virus-related illness. Am J Med Sci. 1993 Feb; 305(2):79-83.

34. Mattison JA, Lane MA, Roth GS, Ingram DK. Calorie restriction in rhesus monkeys. Exp Gerontol. 2003 Jan-Feb; 38(1-2):35-46.

35. Catalina F, Kumar V, Milewich L, Bennett M. Food restriction-like effects of dehy- droepiandrosterone: decreased lymphocyte numbers and functions with increased apoptosis. Proc Soc Exp Biol Med. 1999 Sep;221(4):326-35.

36. Wang TT, Hursting SD, Perkins SN, Phang JM. Effects of dehydroepiandrosterone and calorie restriction on the Bcl-2/Bax- mediated apoptotic pathway in p53-deficient mice. Cancer Lett. 1997 Jun 3;116(1):61-9.

37. Roberts E. The importance of dehydroepiandrosterone sulfate in the blood of primates: a longer and healthier life? Biochem Pharmacol. 1999 Feb 15;57(4):329-46.

38. Shock NW, et al, eds. Normal Human Aging: the Baltimore Longitudinal Study on Aging. Washington, DC: US Government Printing Office;1984.

39. Roth GS, Lane MA, Ingram DK, et al. Biomarkers of calorie restriction may predict longevity in humans. Science. 2002 Aug 2; 297(5582):811.

40. Ravaglia G, Forti P, Maioli F, et al.. The relationship of dehydroepiandrosterone sulfate (DHEAS) to endocrine-metabolic parameters and functional status in the oldest-old. Results from an Italian study on healthy free-living over-ninety-year- olds. J Clin Endocrinol Metab. 1996 Mar;81(3):1173-8.

41. Ravaglia G, Forti P, Maioli F, et al. Determinants of functional status in healthy Italian nonagenarians and centenarians: a comprehensive functional assessment by the instruments of geriatric practice. J Am Geriatr Soc. 1997 Oct;45(10):1196-202.

42. van den Beld AW, Lamberts SW. The male climacterium: clinical signs and symptoms of a changing endocrine environment. Prostate Suppl. 2000;10:2-8.

43. Yang NC, Jeng KC, Ho WM, Hu ML. ATP depletion is an important factor in DHEA-induced growth inhibition and apoptosis in BV-2 cells. Life Sci. 2002 Mar 15;70(17):1979-88.

44. Schulz S, Klann RC, Schonfeld S, Nyce JW. Mechanisms of cell growth inhibition and cell cycle arrest in human colonic ade- nocarcinoma cells by dehydroepiandros- terone: role of isoprenoid biosynthesis. Cancer Res. 1992 Mar 1;52(5):1372-6.

45. Loria RM. Immune up-regulation and tumor apoptosis by androstene steroids. Steroids. 2002 Nov;67(12):953-66.

46. Dashtaki R, Whorton AR, Murphy TM, Chitano P, Reed W, Kennedy TP. Dehydroepiandrosterone and analopgs inhibit DNA binding of AP-1 and airway smooth muscle proliferation. J Pharmacol Exp Ther. 1998 May; 285(2); 876-83.

47. Wang TT, Hursting SD, Perkins SN, Phang JM. Effects of dehydroepiandrosterone and calorie restriction on the Bcl-2/Bax- mediated apoptotic pathway in p53-deficient mice. Cancer Lett. 1997 Jun 3;116(1):61-9.

48. Aoki K, Nakajima A, Mukasa K, Osawa E, Mori Y, Sekihara H. Prevention of diabetes, hepatic injury, and colon cancer with dehydroepiandrosterone. J Steroid Biochem Mol Biol. 2003 Jun;85(2-5):469- 72.

49. Marx C, Petros S, Bornstein SR, et al. Adrenocortical hormones in survivors and nonsurvivors of severe sepsis: diverse time course of dehydroepiandrosterone, dehy- droepiandrosterone-sulfate, and cortisol. Crit Care Med. 2003 May;31(5):1382-8.

50. Barret-Conner E, Knaw KT, Yen SS. A prospective study of dehydroepiandrosterone sulfate, mortality and cardiovascular disease. N Engl J Med. 1986 Dec 11; 315(24):1519-24.

51. Mulder JW, Frissen PH, Kirjnen P, et al. Dehydroepiandrosterone as predictor for progression to AIDS in asymptomatic HIV-infected men. J Infect Dis. 1992; 165(3):413-418.

52. Yasushi M, Hirofumi Y, Michihiro Y, Yuki M, Koichi N, et al. Plasma levels of dehydroepiandrosterone sulfate are decreased in patients with chronic heart failure in proportion to the severity. J Clin Endocrinol Metab. 2000 May; 85(5):1834-40.

53. Nagai T, Noda Y, Nozaki A, Nabeshima T. Neuroactive steroid and stress response. Nihon Shinkei Seishin Yakurigaku Zasshi. 2001 Nov;21(5):157-62.

54. van den Beld AW, Bots ML, Janssen JA, Pols HA, Lamberts SW, Grobbee DE. Endogenous hormones and carotid atherosclerosis in elderly men. Am J Epidemiol. 2003 Jan 1;157(1):25-31.

55. Solerte SB, Fioravanti M, Vignati G, Giustina A, Cravello L, Ferrari E. DHEA sulfate enhances natural killer cell cytotoxicity in humans via locally generated immunoreactive insulin-like growth factor I. J Clin Endocrinol Metab. 1999 Sep;84(9):3260-7.

56. Khorram O, Vu L, Yen SS. Activation of immune function by dehydroepiandrosterone (DHEA) in age-advanced men. J Gerontol A Biol Sci Med Sci. 1997 Jan;52(1):M1-7.

57. Assan R, Robel P, Baulieu EE. Dehydroepiandrosterone (DHEA) for diabetic patients? Eur J Endocrinol. 1996 Jul; 135(1):37-8.

58. Casson PR, Hornsby PJ, Buster JE. Adrenal androgens, insulin resistance, and cardiovascular disease. Semin Reprod Endocrinol. 1996 Feb;14(1):29-34.

59. Beer NA, Jakubowicz DJ, Matt DW, Beer RM, Nestler JE. Dehydroepiandrosterone reduces plasma plasminogen activator inhibitor type 1 and tissue plasminogen activator antigen in men. Am J Med Sci. 1996 May;311(5):205-10

60. Casson PR, Anderson RN, Herrod HG, et al. Oral dehydroepiandrosterone in physiologic doses modulates immune function in postmenopausal women. Am J Obstet Gynecol. 1993 Dec; 169(6):1536-9.

61. Chang DM, Lan JL, Lin HY, Luo SF. Dehydroepiandrosterone treatment of women with mild to moderate systemic lupus erythematosus: a multicenter randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2002 Nov; 46(11):2924-7.

62. Gelato MC. Aging and immune function: a possible role for growth hormone. Horm Res. 1996;45(1-2):46-9.

63. Sacco M, Valenti G, Corvi Mora P, Wu FC, Ray DW. DHEA, a selective glucocorticoid receptor antagonist: its role in immune system regulation and metabolism. J Endocrinol Invest. 2002;25(10 Suppl):81-2.

64. Bradlow HL, Sepkovic DW. Diet and breast cancer. Ann NY Acad Sci. 2002 Jun;963:247-67.

65. Mei JJ, Hursting SD, Perkins SN, Phang JM. p53-independent inhibition of nitric oxide generation by cancer preventive interventions in ex vivo mouse peritoneal macrophages. Cancer Lett. 1998 Jul 17;129(2):191-7.

66. D’Ambrosio SM, Gibson-D’Ambrosio RE, Wani G, et al. Modulation of Ki67, p53 and RARbeta expression in normal, premalignant and malignant human oral epithelial cells by chemopreventive agents. Anticancer Res. 2001 Sep-Oct;21(5):3229- 35.

67. Weber E, Moore MA, Bannasch P. Phenotypic modulation of hepatocarcinogenesis and reduction in N-nitrosomor- pholine-induced hemangiosarcoma and adrenal lesion development in Sprague- Dawley rats by dehydroepiandrosterone. Carcinogenesis. 1988 Jul;9(7):1191-5.

68. Prough RA, Lei XD, Xiao GH, Wu HQ, Geoghegan TE, Webb SJ. Regulation of cytochrome P450 by DHEA and its anticarcinogenic action. Ann NY Acad Sci. 1995 Dec 29;774:187-99.

69. Schwartz AG, Pashko LL. Cancer prevention with DHEA and nonandrogenic structural analogs. J Cell Biochem Suppl.1995;22:210-217.

70. Inano H, Ishii-Ohba H, Suzuki K, Yamanouchi H, Onoda M, Wakabayashi K. Chemoprevention by dietary dehydroepiandrosterone against promotion / progression phase of radiation-induced mamary tumorigenesis in rats. J Steroid Biochem and Mol Biol. 1995 Jul; 54(1- 2):47-53.

71. Poetschke HL, Klug DB, Hursting SD, Richie ER. The effect of chemoprotective steroids on thymocyte and thymic epithelial cell development. FASEB Journal. 1999; 13(4):A623.

72. Greenwald P, Kelloff GJ, Boone CW, McDonald SS. Genetic and cellular changes in colorectal cancer: proposed targets of chemoprotective agents. Cancer Epidemiol Biomarkers Prev. 1995 Oct-Nov; 4(7):691-702.

73. Melvin WS, Boros LG, Muscarella P, et al. Dehydroepiandrosterone-sulfate inhibits pancreatic carcinoma cell proliferation in vitro and in vivo. Surgery. 1997 Apr;121(4):392-7.

74. Hursting SD, Perkins SN, Haines DC, Ward JM, Phang JM. Chenoprevention of spontaneous tumorigenesis in p53 knock-out mice. Cancer Res. 1995 Sep; 15;55(18);3949-53.

75. Ledochowski M, Murr C, Jager M, Fuchs D. Dehydroepiandrosterone, ageing and immune activation. Exp Gerontol. 2001 Nov; 36:1739-47.

76. Metzger C, Bannasch P, Mayer D. Enhancement and phenotypic modulation of N-nitrosomorpholine-induced hepatocarcinogenesis by dehydroepiandrosterone. Cancer Lett. 1997 Dec 23;121(2):125-31.

77. Moore MA, Weber E, Thorton M, Bannasch P. Sex-dependent, tissue-specific opposing effects of dehydroepiandrosterone on initiation and modulation stages of liver and lung carcinogenesis induced by dihydroxy-di-n-propylnitrosamine in F344 rats. Carcinogenesis. 1988 Aug; 9(8):1507-9.

78. Williams JR. The effects of dehydroepiandrosterone on carcinogenesis, obesity, the immune system and aging. Lipids. 2000 Mar; 35(3):325-31.

79. Orner GA, Mathews C, Hendricks JD, Carpenter HM, Bailey GS, Williams DE. Dehydroepiandrosterone is a complete hepatocarcinogen and potent tumor promoter in the absence of peroxisome proliferation in rainbow trout. Carcinogenesis. 1995 Dec;16(12):2893-8.

80. Jozuka H, Jozuka E, Suzuki M, Takeuchi S, Takatsu Y. Psycho-neuro-immunological treatment of hepatocellular carcinoma with major depression. Curr Med Res Opin. 2003;19(1):59-63.

81. Kavanaugh C, Green JE. The use of genetically altered mice for breast cancer prevention studies. J Nutr. 2003 Jul; 133(7 Suppl):2404S-2409S.

82. Regelson W, Loria R, Kalimi M. Dehydroepiandrosterone (DHEA) I: immunologic action. Ann NY Acad Sci. 1994 May 31;719:553-563.

83. Green JE, Shibata MA, Shibata E, et al. 2-Difluoromethylornithine and dehy- droepiandrosterone inhibit mammary tumor progression but not mammary or prostate tumor initiation in C3(1)/SV40 T/t-antigen transgenic mice. Cancer Res. 2001 Oct 15;61(20):7449-55.

84. Perkins SN, Hursting SD, Kim K, Poetschke K, Heather L, Richie ER. Mechanisms underlying the anti-lymphoma activity of dehydroepiandrosterone: studies in murine thymocytes and murine T-cell hybridoma cells. Cancer Epidemiology Biomarkers & Prevention. 2002; 11(10):1233s.

85. Perkins SN, Hursting SD, Haines DC, James SJ, Miller BJ, Phang JM. Chemoprevention of spontaneous tumorigenesis in nullizygous p53-deficient mice by dehydroepiandrosterone and its analog 16alpha-fluoro-5-androsten-17-one. Carcinogenesis. 1997 May;18(5):989-94.

86. Perkins SN. Dietary modulation of cell cycle regulators. NCI grant. Federal research in progress (FRP). NDN 049- 0652-1518-9.

87. Hsu HC. Dehydroepiandrosterone (DHEA) sulfotransferase gene expression in human hepatocellular carcinoma: an age-dependent prognostic factor. Proc Am Assoc Cancer Res. 1995;36:208.

88. Osawa E, Hakajima A, Yoshida S, et al. Chemoprevention of precursors to colon cancer by dehydroepiandrosterone (DHEA). Life Sci. 2002 Apr 19; 70(22):2623-30.

89. Yang S, FuZ, Wang F, Cao Y, Han R. Antimutagenic activity of dehydroepiandrosterone. Zhonghua Zhong Liu Za Zhi. 2002 Mar; 24(2):137-40.

90. Bulbrook RD, Hayward JL, Spicer CC. Relation between urinary androgen and corticoid excretion and subsequent breast cancer. Lancet. 1971 Aug 21; 2(7721):395- 98.

91. Eaton NE, Reeves GK, Appleby PN, Key TJ. Endogenous sex hormones and prostate cancer: a quantitative review of prospective studies. Br J Cancer. 1999 Jun;80(7):930-4.

92. Vatten LJ, Ursin G, Ross RK, et al. Androgens in serum and the risk of prostate cancer: a nested case-control study from the Janus serum bank in Norway. Cancer Epidemiol Biomarkers Prev.1997 Nov;6(11):967-9.

93. Stahl F, Schnorr D, Pilz C, Dorner G. Dehydroepiandrosterone (DHEA) levels in patients with prostatic cancer, heart disease, and under surgery stress. Exp Clin Endocrinol. 1992; 99(2):68-70.

94. Schatzl G, Madersbacher S, Thurridl T, et al. High-grade prostate cancer is associated with low serum testosterone levels. Prostate. 2001 Apr;47(1):52-8.

95. Schatzl G, Reiter WJ, Thurridl T, et al. Endocrine patterns in patients with benign and malignant prostatic diseases. Prostate. 2000 Aug;44(3):219-24.

96. Huot RI, Shain SA. Differential metabolism of dehydroepiandrosterone sulfate and estrogen conjugates by normal or malignant AXC/SSh rat prostate cells and effects of these steroid conjugates on cancer cell proliferation in vitro. J Steroid Biochem. 1988 Jun;29(6):617-21.

97. McCormick DL, Rao KV. Chemoprevention of hormone-dependent prostate cancer in the Wistar- Unilever rat. Eur Urol. 1999 May;35(5- 6):464-7.

98. Ponholzer A, Plas E, Schatzl G, Jungwirth A, Maderbacher S. Association of DHEA- S and estradiol serum levels to symptoms of aging men. Aging Male. 2002 Dec; 5(4):233-8.

99. Sun Y, Mao M, Sun L, Feng Y, Yang J, Shen P. Treatment of osteoporosis in men using dehydroepiandrosterone sulfate. Chin Med J. (Engl) 2002; 115(3):402-4.

100. Wallace MB, Lim J, Cutler A, Bucci L. Effects of dehydroepiandrosterone vs androstenedione supplementation in men. Med Sci Sports Exerc. 1999 Dec; 31(12):1788-92.

101. Miyamoto H, Marwah P, Marwah A, Lardy H, Chang C. 3 beta-acetoxyandrost- 1,5-diene-17-ethylene ketal functions as a potent antiandrogen with marginal agonist activity. Proc Natl Acad Sci (USA). 2003 Apr 15; 100(8):4440-4.

102. Greenwald P. Cancer risk factors for selecting cohorts for large scale chemo prevention trials. J Cell Biochem Suppl. 1996;25:29-36.

103. Reiter WJ, Schatzl G, Zeiner A, Pycha A, Merberger M. Dehydroepiandrosterone in the treatment of erectile dysfunction in patients with different organic etiologies. Urol Res. 2001 Aug; 29(4):278-81.

104. Reiter WJ, Pycha A, Schatzl G. Dehydroepiandrosterone in the treatment of erectile dysfunction: a prospective, double-blind, randomized, placebo-controlled study. Urology. 1999 Mar;53(3):590-94.

105. Steel N. Dehydroepiandrosterone and aging. Age Ageing. 1999 Mar;28(2):89-91.

106. Cutting CW, Hunt C, Nisbet JA, Bland JM, Dalgleish AG, Kirby RS. Serum insulin-like growth factor-1 is not a useful marker of prostate cancer. BJU Int. 1999 Jun;83(9):996-9.

107. Woodson K, Tangrea JA, Pollak M, et al. Serum insulin-like growth factor I: tumor marker or etiologic factor? A prospective study of prostate cancer among Finnish men. Cancer Res. 2003 Jul 15; 63(14):3991-4.

108. Wan JM, Istfan NW, Ye SL, Bistrian BR. Insulin-like growth factor-1 is not mitogenic for the Walker-256 carcinosarcoma. Life Sci. 1995 Jan 27;56(10):747-56.

109. Sonntag WE, Lynch C, Thornton P, Khan A, Bennett S, Ingram R. The effects of growth hormone and IGF-1 deficiency on cerebrovascular and brain aging. J Anat.2000 Nov;197 Pt 4:575-85.

110. Haden ST, Glowacki J, Hurwitz S, Rosen C, LeBoff MS. Effects of age on serum dehydroepiandrosterone sulfate, IGF-I, and IL-6 levels in women. Calcif Tissue Int. 2000 Jun;66(6):414-8.

111. Ravaglia G, Forti P, Maioli F, et al. Body composition, sex steroids, IGF-1, and bone mineral status in aging men. J Gerontol A Biol Sci Med Sci. 2000 Sep;55(9):M516-21.

112. Calo L, Castrignano R, Davis PA, et al. Role of insulin-like growth factor-I in primary osteoporosis: a correlative study. J Endocrinol Invest. 2000 Apr;23(4):223-7

113. Carro E, Trejo JL, Gomez-Isla T, LeRoith D, Torres-Aleman I. Serum insulin-like growth factor-I regulates brain amyloid- B levels. Nat Med. 2002 Dec;8(12):1390-7.

114. Ruiz-Torres A, Soares de Meo Kirzner M. Aging and longevity are related to growth hormone/insulin-like growth factor-I secretion. Gerontology. 2002 Nov; 48(6):401-7.

115. Yoshida S, Honda A, Matsuzaki Y, et al. Antiproliferative action of endogenous dehydroepiandrosterone metabolites on human cancer cell lines. Steroids. 2003 Jan;68(1):73-83.

116. Simoncini T, Mannella P, Fornari L, Varone G, Caruso A, Genazzani AR. Dehydroepiandrosterone modulates endothelial nitric oxide synthesis via direct genomic and nongenomic mechanisms. Endocrinology. 2003 Aug;144(8):3449-55.

117. Postmenopausal hormone therapy: cardiovascular risks. Prescrire Int. 2003 Apr;12(64):65-9.

118. Jusko WJ, Blum RA, Meno-Tetang, Guy ML, Schwartz KE. Effects of oral dehy- droepiandrosterone on single dose pharmacokinetics or oral prednisone and cortisol suppression in normal women. J Clin Pharmacol. 2001;41(11):1195-1205.

119. Bernardi F, Pieri M, Stomati M, et al. Effect of different hormonal replacement therapies on circulating allopregnanolone and dehydroepiandrosterone levels in postmenopausal women. Gynecol Endocrinol. 2003 Feb;17(1):65-77.

120. Takayanagi R, Goto K, Suzuki S, Tanaka S, Shimoda S, Nawata H. Dehydroepiandrosterone (DHEA) as a possible source for estrogen formation in bone cells: correlation between bone mineral density and serum DHEA-sulfate concentration in postmenopausal women, and the presence of aromatase to be enhanced by 1.25-dihydroxyvitamin D3 in human osteoblasts. Mech Ageing Dev. 2002 Apr 30;123(8):1107-14.

121. Genazzani AD, Stomati M, Strucchi C, Puccetti S, Luisi S, Genazzani AR. Oral dehydroepiandrosterone supplementation modulates spontaneous and growth hormone-releasing hormone-induced growth hormone and insulin-like growth factor-1 secretion in early and late postmenopausal women. Fertil Steril. 2001 Aug;76(2):241-8.

122. Kalimi M, Regelson W, eds. The Biological Role of Dehydroepiandrosterone (DHEA). Berlin:Walter de Gruyter; 1990.

123. Legrain S, Massien C, Lahlou N, et al. Dehydroepiandrosterone replacement administration: pharmacokinetic and pharmacodynamic studies in healthy elderly subjects. J Clin Endocrinol Metab. 2000 Sep;85(9):3208-17.

124. Baulieu EE, Thomas G, Legrain S, et al. Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: contribution of the DHEAge Study to a sociobiomedical issue. Proc Natl Acad Sci USA. 2000 Apr 11;97(8):4279-84.

125. Tode T, Kikuchi Y, Hirata J, Kita T, Nakata H, Nagata I. Effect of Korean red ginseng on psychological functions in patients with severe climacteric syndromes. Int J Gynaecol Obstet. 1999 Dec;67(3):169-74.

126. Copeland JL, Consitt LA, Tremblay MS. Hormonal responses to endurance and resistance exercise in females aged 19-69 years. J Gerontol A Biol Sci Med Sci. 2002 Apr;57(4):B158-65.

127. Tissandier O, Peres G, Fiet J, Piette F. Testosterone, dehydroepiandrosterone, insulin-like growth factor 1, and insulin in sedentary and physically trained aged men. Eur J Appl Physiol. 2001 Jul;85(1- 2):177-84.

128. Bonnefoy M, Patricot MC, Lacour JR, Rahmani A, Berthouze S, Kostka T. Relation between physical activity, muscle function and IGF-1, testosterone and DHEAS concentrations in the elderly. Rev Med Interne. 2002 Oct;23(10):819-27.

129. Ando S, Rubens R, Rottiers R. Androgen plasma levels in male diabetics. J Endocrinol Invest.1985;7:21-4.

130. Barrett-Conner E. Lower endogenous androgen levels and dyslipidemia in men with noninsulin-dependent diabetes mellitus. Ann Intern Med. 1992;117:807-11.

131. Thomas N, Morris HA, Scopacasa F, Wishart JM, Need AG. Relationships between age, dehydroepiandrosterone sulphate and plasma glucose in healthy men. Age Ageing. 1999 Mar;28(2):217-20.

132. Johnson R. Abnormal testosterone: epitestosterone ratios after DHEA supplementation. Clin Chemistry. 1999; 45:163-4.

133. Salek FS, Bigos KL, Kroboth PD. The influence of hormones and pharmaceutical agents on DHEA and DHEA-S concentrations: a review of clinical studies. J Clin Pharmacol. 2002 Mar;42(3):247-66.

134. Moore TJ, Psaty BM, Furberg CD. Time to act on drug safety. JAMA. 1998 May 20; 279(19):1571-3.

135. Kruuse C, Thomsen LL, Birk S, Olesen J. Migraine can be induced by sildenafil without changes in middle cerebral artery diameter. Brain. 2003 Jan;126(Pt 1):241-7.

136. Azarbal B, Mirocha J, Shah PK, Cerek B, Kaul S. Adverse cardiovascular events associated with the use of Viagra®. J Am Col Cardiol. 2000; 35 (Suppl A): 553A- 554A.

137. Meno-Tetang GM, Blum RA, Schwartz KE, Jusko WJ. Effects of oral prasterone (dehydroepiandrosterone) on single-dose pharmacokinetics of oral prednisone and cortisol suppression in normal women. J Clin Pharmacol. 2001 Nov; 41(11):1195- 205.

138. Gennari R, Alexander JW. Arginine, glutamine, and dehydroepiandrosterone reverse the immunosuppressive effect of prednisone during gut-derived sepsis. Crit Care Med. 1997 Jul;25(7):1207-14.

139. Petri MA, Lahita RG, Van Vollenhoven RF, et al. Effects of prasterone on corticosteroid requirements of women with systemic lupus erythematosus; a double- blind, randomized, placebo-controlled trial. Arthritis Rheum. 2002 Jul; 46(7):1820-9.

140. Zietz B, Hrach S, Scholmerich J, Straub RH. Differential age-related changes of hypothalamus-pituitary-adrenal axis hormones in healthy women and men: role of interleukin-6. Exp Clin Endocrinol Diabetes. 2001;109(2):93-101.

141. Straub RH, Konecna L, Hrach S, et al. Serum dehydroepiandrosterone (DHEA) and DHEA sulfate are negatively correlat- ed with serum interleukin-6 (IL-6), and DHEA inhibits IL-6 secretion from mononuclear cells in man: possible link between endocrinosenescence and immunosenescence. J Endocrinol Metab. 1998 Jun; 83(6):2012.7.

142. Straub RH, Lehle K, Herfarth H, et al. Dehydroepiandrosterone in relation to other adrenal hormones during an acute inflammatory stressful disease state compared with chronic inflammatory disease: role of interleukin-6 and tumor necrosis factor. Eur J Endocrinol. 2002 Mar; 146(3):365-74.

143. Vogl D, Falk W, Dorner M, Scholmerich J Straub RH. Serum levels of pregnenolone and 17-hydroxypregnenolone in patients with rheumatoid arthritis and systemic lupus erythematosis: relation to other adrenal hormones. J Rheumatol. 2003 Feb;30(2):269-75.

144. Cutolo M, Strab RH, Foppiani L, et al. Adrenal gland hypofunction in active polymyalgia rheumatica; effect of glucocorticoid treatment on adrenal hormones and interleukin-6. J Rheumatol. 2002 Apr; 29(4):748-56.

145. Andus T, Klebl F, Rogler G, Bregenzer N, Scholmerich J, Straub RH. Patients with refractory Crohn’s disease or ulcerative colitis respond to dehydroepiandrosterone: a pilot study. Aliment Pharmacol Ther. 2003 Feb; 17(3):409-14.

146. Straub RH, Scholmerich J, Zietz B. Replacement therapy with DHEA plus corticosteroids in patients with chronic inflammatory diseases – substitutes of adrenal and sex hormones. Z Rheumatol. 2002; 59:Suppl 2:108-118.

147. Osorio A, Vara-Thorbeck R, Rosell J, Osorio C, Ortega E, Ruiz-Requena E. Dehydroepiandrosterone sulfate and growth axis hormones in patients after surgery. World J Surg. 2002 Sep;26(9):1079-82. Epub 2002 Aug 16.

148. Canbaz S, EgeT, Sunar H, Cikirikcioglu M, Acipayam M, Duran E. The effects of cardiopulmonary bypass on androgen hor- mones in coronary artery bypass surgery. J Int Med Res. 2002 Jan-Feb; 30(1):9-14.

149. National Institute of Mental Health. Depression. Available at: http:// www.nimh.nih.gov/publicat/depression.

com. Accessed January 13, 2004.

150. Wolkowitz OM, Reus VI. Neurotransmitters, neurosteroids and neurotrophins: new models of the patho- physiology and treatment of depression. World J Biol Psychiatry. 2003 Jul;4(3):98-102. 151. Young AH, Gallagher P, Porter RJ. Elevation of the cortisol-dehydroepiandrosterone ratio in drug-free depressed patients. Am J Psychiatry. 2002 Jul;159(7):1237-9.

152. Giordano R, DiVito L, Lanfranco F, et al. Elderly subjects show severe impairment of dehydroepiandrosterone sulfate and reduced sensitivity of cortisol and aldosterone response to the stimulatory effect of ACTH. Clin Endocrinol. (Oxf) 2001 Aug;55(2):259-65.

153. Weill-Engerer S, David JP, Sazdovitch V, et al. Neurosteroid quantification in human brain regions; comparison between Alzheimer’s and nondemented patients. J Clin Endocrinol Metab. 2002 Nov; 87(11):5138-43.

154. Valenti G. Andrenopause: an imbalance between dehydroepiandrosterone (DHEA) and cortisol secretion. J Endocrinol Invest. 2002;25(10 suppl):25- 35.

155. Magri F, Terenzi F, Ricciardi T, et al. Association between changes in adrenal secretion and cerebral morphometric cor- relates in normal aging and senile dementia. Dement Geriatr Cogn Disord. 2000 Mar-Apr; 11(2):90-9.

156. Karishma KK, Herbert J. Dehydroepiandrosterone (DHEA) stimulates neurogenesis in the hippocampus of the rat, promotes survival of newly formed neurons and prevents corticosterone- induced suppression. Eur J Neurosci. 2002 Aug;16(3):445-53.

157. Strous RD, Maayan R, Lapidus R, et al. Dehydroepiandrosterone augmentation in the management of negative, depressive, and anxiety symptoms in schizophrenia. Arch Gen Psychiatry. 2003 Feb;60(2):133- 41.

158. Office of Technology Assessment, US Congress. Assessing the Efficacy and Safety of Medical Technologies. Washington, DC: Office of Technology Assessment, US Congress; 1978.

159. Jia Q, Hong MF, Cherniske S. Measurement and Quantification of 17 Ketosteroid-Sulfates as a Biomarker of Biological Age. US patent 6,326,209 B1, Dec. 4, 2001.

160. Jia Q, Hong MF, Zhao XP, Orndorff S. Quantification of urine 17-ketosteroid sulfates and glucuronides by high-performance liquid chromatography-ion trap mass spectroscopy. Journal of Chromatography B, Biomed Sci Appl. 2001 Jan 5; 750(1):81-91.

161. Qi Jia, Mei-Feng Hong, Zhao-Xing Pan, et al. Quantification of urine 17-ketosteroid sulfates and their age correlations. Spectroscopy. 2002;16:171-81.